GSK mRNA flu vaccine Phase 3 advance validates platform, lifts Moderna

 

GSK mRNA flu vaccine Phase 3 advance validates platform, lifts Moderna 9%

• GSK progressed its rival mRNA-based flu candidate to Phase 3, seen as strong validation of the technology.
• Moderna recently gained FDA approval for mFLUSIVA (mRNA-1010), its own mRNA flu shot for adults 50+, with superior efficacy data.
• Positive read-through boosts confidence in Moderna's respiratory franchise and broader mRNA platform.
• Extends momentum from August's landmark Phase 3 success of personalized cancer vaccine (intismeran autogene) + Keytruda in melanoma.
• Stock up massively YTD (>400%) and volatile post-cancer news but supported by oncology pipeline optionality.
• Elevated trading interest with no offsetting negative headlines today.
• Analysts highlight potential for flu/COVID combos and further cancer indications as long-term drivers.

https://finviz.com/stock?t=MRNA&ty=c&ta=1&p=d